Skip to main content
SpringerLink
Log in

Insulin-Like Growth Factor-1 Receptor as a Target for Anticancer Therapy

  • Chapter
Apoptosis and Cancer Chemotherapy

Part of the book series: Cancer Drug Discovery and Development ((CDD&D))

Abstract

The type 1 receptor for the insulin-like growth factors (IGF-1R) plays a major role in the control of cell proliferation, both in vitro and in vivo. Downregulation of the IGF-1R function by a variety of procedures causes large-scale apoptosis of cells, especially when the cells are in anchorage-independent conditions. The ability of the targeted IGF-1R to discriminate between contact-inhibited cells and cells in anchorage-independence has been exploited in animals to abrogate tumor growth.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Baserga R. Biology of Cell Reproduction. Harvard University Press: Cambridge, MA. 1985.

    Google Scholar 

  2. Baserga R, Kisieleski. Comparative study of the kinetics of cellular proliferation of normal and tumorous tissues with the use of tritiated thymidine. J Natl Cancer Inst 1962; 28: 331–339.

    CAS  PubMed  Google Scholar 

  3. Steel GG, Adams K, Barrett JC. Analysis of the cell population kinetics of transplanted tumours of widely differing growth rates. Br J Cancer 1966; 20: 784–800.

    Article  CAS  PubMed  Google Scholar 

  4. Baserga R, Hongo A, Rubini M, Prisco M, Valentinis B. The IGF-I receptor in cell growth, transformation and apoptosis. Biochim Biophys Acta 1997; 1332: 105–126.

    Google Scholar 

  5. Arteaga CL, Kitten LJ, Coronado EB, Jacobs S, Kull FC, Allred DC, Osborne CK. Blockade of the type 1 somatomedin receptor inhibits growth of human breast cancer cells in athymic mice. J Clin Invest 1989; 84: 1418–1423.

    Article  CAS  PubMed  Google Scholar 

  6. Resnicoff M, Sell C, Rubini M, Coppola D, Ambrose D, Baserga R, Rubin R. Rat glioblastoma cells expressing an antisense RNA to the insulin-like growth factor I (IGF-I) receptor are non-tumorigenic and induce regression of wild-type tumors. Cancer Res 1994; 54: 2218–2222.

    CAS  PubMed  Google Scholar 

  7. Resnicoff M, Coppola D, Sell C, Rubin R, Ferrone S, Baserga R. Growth inhibition of human melanoma cells in nude mice by antisensense strategies to the type 1 insulin-like growth factor receptor. Cancer Res 1994; 54: 4848–4850.

    CAS  PubMed  Google Scholar 

  8. Prager D, Li HL, Asa S, Melmed S. Dominant negative inhibition of tumorigenesis in vivo by human insulin-like growth factor receptor mutant. Proc Natl Acad Sci USA 1994; 91: 2181–2185.

    Article  CAS  PubMed  Google Scholar 

  9. D’Ambrosio C, Ferber A, Resnicoff M, Baserga R. A soluble insulin-like growth factor I receptor that induces apoptosis of tumor cells in vivo and inhibits tumorigenesis. Cancer Res 1996; 56: 4013–4020.

    PubMed  Google Scholar 

  10. Baker J, Liu J-P, Robertson EJ, Efstratiadis A. Role of insulin-like growth factors in embryonic and postnatal growth. Cell 1993; 75: 73–82.

    CAS  PubMed  Google Scholar 

  11. Liu J-P, Baker J, Perkins AS, Robertson EJ, Efstratiadis A. Mice carrying null mutations of the genes encoding insulin-like growth factor I (igf-1) and type 1 IGF receptor (Igflr). Cell 1993; 75: 59–72.

    CAS  PubMed  Google Scholar 

  12. Ludwig T, Eggenschwiler J, Fisher P, D’Ercole JP, Davenport ML, Efstratiadis A. Mouse mutants lacking the type 2 IGF receptor (IGF2R) are rescued from perinatal lethality in Igf2 and Igflr null backgrounds. Dev Biol 1996; 177: 517–535.

    Article  CAS  PubMed  Google Scholar 

  13. Morrione A, Valentinis B, Xu SQ, Yumet G, Louvi A, Efstratiadis A, Baserga R. Insulin-like growth factor II stimulates cell proliferation through the insulin receptor. Proc Natl Acad Sci USA 1997; 94: 3777–3782.

    Article  CAS  PubMed  Google Scholar 

  14. Louvi A, Accili D, Efstratiadis A. Growth-promoting interaction of IGF-II with the insulin receptor during mouse embryonic development. Dev Biol 1997; 189: 33–48.

    Article  CAS  PubMed  Google Scholar 

  15. Sell C, Rubini M, Rubin R, Liu J-P, Efstratiadis A, Baserga R. Simian virus 40 large tumor antigen is unable to transform mouse embryonic fibroblasts lacking type-1 insulin-like growth factor receptor. Proc Natl Acad Sci USA 1993; 90: 11, 217–11, 221.

    Google Scholar 

  16. Baserga R. The price of independence. Exp Cell Res 1997; 236: 1–3.

    Article  CAS  PubMed  Google Scholar 

  17. Resnicoff M, Abraham D, Yutanawiboonchai W, Rotman H, Kajstura J, Rubin R, Zoltick P, Baserga R. The insulin-like growth factor I receptor protects tumor cells from apoptosis in vivo. Cancer Res 1995; 55: 2463–2469.

    CAS  PubMed  Google Scholar 

  18. Long L, Rubin R, Baserga R, Brodt P. Loss of the metastatic phenotype in murine carcinoma cells expressing an antisense RNA to the insulin-like growth factor I receptor. Cancer Res 1995; 55: 1006–1009.

    CAS  PubMed  Google Scholar 

  19. Reiss K, Ambrosio L, Yu X, Baserga R. Inhibition of tumor growth by a dominant negative mutant of the insulin-like growth factor 1 receptor with a bystander effect. Clin Cancer Res 1998; 4: 2647–2655.

    CAS  PubMed  Google Scholar 

  20. Harrington EA, Bennett MR, Fanidi A, Evan GI. c-myc-induced apoptosis in fibroblasts is inhibited by specific cytokines. EMBO J 1994; 13: 3286–3295.

    CAS  PubMed  Google Scholar 

  21. O’Connor R, Kauffmann-Zeh A, Liu Y, Lehar S, Evan GI, Baserga R, Blattler WA. The IGF-I receptor domains for protection from apoptosis are distinct from those required for proliferation and transformation. Mol Cell Biol 1997; 17: 427–435.

    PubMed  Google Scholar 

  22. Prisco M, Hongo A, Rizzo MG, Sacchi A, Baserga R. The IGF-I receptor as a physiological relevant target of p53 in apoptosis caused by Interleukin-3 withdrawal. Mol Cell Biol 1997; 17: 1084–1092.

    CAS  PubMed  Google Scholar 

  23. Kennedy SG, Wagner AJ, Conzen SD, Jodan J, Bellacosa A, Tsichlis PN, Hay N. The PI 3-kinase/Akt signaling pathway delivers an anti-apoptotic signal. Genes Dev 1997; 11: 701–713.

    Article  CAS  PubMed  Google Scholar 

  24. Kulik G, Klippel A, Weber MJ. Antiapoptotic signaling by the insulin-like growth factor I receptor, phosphatidylinositol 3-kinase, and Akt. Mol Cell Biol 1997; 17: 1595–1606.

    CAS  PubMed  Google Scholar 

  25. Parrizas M, Saltiel AR, LeRoith D. Insulin-like growth factor I inhibits apoptosis using the phosphatidylinositol 3’-kinase and mitogen-activated protein kinase pathways. J Biol Chem 1997; 272: 154–161.

    Article  CAS  PubMed  Google Scholar 

  26. Backer JM, Myers MG Jr, Sun XJ, Chin DJ, Shoelson SE, Miralpeix M, White MF. Association of IRS-1 with the insulin receptor and the phosphatidylinositol 3’-kinase. J Biol Chem 1993; 268: 8204–8212.

    CAS  PubMed  Google Scholar 

  27. White MF, Kahn CR. The insulin signaling system. J Biol Chem 1994; 269: 1–4.

    CAS  PubMed  Google Scholar 

  28. Datta SR, Dudek H, Tao X, Masters S, Fu H, Gotoh Y, Greenberg ME. Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell 1997; 91: 231–241.

    Article  CAS  PubMed  Google Scholar 

  29. Dudek H, Datta SR, Franke TF, Birnbaum MJ, Yao R, Cooper GM, et al. Regulation of neuronal survival by the serine-threonine protein kinase Akt. Science 1997; 275: 661–665.

    Article  CAS  PubMed  Google Scholar 

  30. Khwaja A, Rodriguez-Viciana P, Wennstrom S, Warne PH, Downward J. Matrix adhesion and ras transformation both activate a phosphoinositide 3-OH kinase and protein kinase B/Akt cellular survival pathway. EMBO J 1997; 16: 2783–2793.

    Article  CAS  PubMed  Google Scholar 

  31. Sell C, Dumenil G, Deveaud C, Miura M, Coppola D, DeAngelis T, et al. Effect of a null mutation of the insulin-like growth factor I receptor gene on growth and transformation of mouse embryo fibroblasts. Mol Cell Biol 1994; 14: 3604–3612.

    CAS  PubMed  Google Scholar 

  32. Zamorano J, Wang HY, Wang L-M, Pierce JH, Keegan AD. IL-4 protects cells from apoptosis via the insulin receptor substrate pathway and a second independent signaling pathway. J Immunol 1996; 157: 4926–4934.

    CAS  PubMed  Google Scholar 

  33. Wang LM, Myers MG Jr, Sun XJ, Aaronson SA, White M, Pierce JH. IRS-1: essential for insulin-and IL-4-stimulated mitogenesis in hemopoietic cells. Science 1993; 261: 1591–1594.

    Article  CAS  PubMed  Google Scholar 

  34. Dews M, Nishimoto I, Baserga R. IGF-I receptor protection from apoptosis in cells lacking IRS proteins. Receptors Signal Transduc 1997; 7: 231–240.

    CAS  Google Scholar 

  35. Stewart AJ, Johnson MD, May, FEB, Westley BR. Role of insulin-like growth factors and the type-1 insulin-like growth factor receptor in the estrogen-stimulated proliferation of human breast cancer cells. JBiol Chem 1990; 265: 21172–21178.

    CAS  Google Scholar 

  36. Rubini M, Hongo A, D’Ambrosio C, Baserga R. The IGF-I receptor in mitogenesis and transformation of mouse embryo cells: role of receptor number. Exp Cell Res 1997; 230: 284–292.

    Article  CAS  PubMed  Google Scholar 

  37. Schmid C, Steiner T, Froesch ER. Preferential enhancement of myoblast differentiation by insulin-like growth factors (IGF-I and IGF-II) in primary cultures of chicken embryonic cells. FEBS Lett 1983; 161: 117–121.

    Article  CAS  PubMed  Google Scholar 

  38. Florini JR, Ewton DZ, Falen SL, van Wyk JJ. Biphasic concentration dependency of stimulation of myoblast differentiation by somatomedins. Am J Physiol 1986; 250: C771 - C778.

    CAS  PubMed  Google Scholar 

  39. Schmid C, Steiner T, Froesch ER. Insulin-like growth factor I supports differentiation of cultured osteoblast-like cells. FEBS Lett 1984; 173: 48–52.

    Article  CAS  PubMed  Google Scholar 

  40. Smith PJ, Wise LS, Berkowitz R, Wan C, Rubin CS. Insulin-like growth factor 1 is an essential regulator of the differentiation of 3T3–L1 adipocytes. J Biol Chem 1988; 263: 9402–9408.

    CAS  PubMed  Google Scholar 

  41. Mill JF, Chao MV, Ishii DN. Insulin, insulin-like growth factor II, and nerve growth factor effects on tubulin mRNA levels and neurite formation. Proc Natl Acad Sci USA 1985; 82: 7126–7130.

    Article  CAS  PubMed  Google Scholar 

  42. Recio-Pinto E, Lanf FF, Ishii DN. Insulin and insulin-like growth factor II permit nerve growth factor binding and the neurite formation response in cultured human neuroblastoma cells. Proc Natl Acad Sci USA 1984, 81: 2562–2566.

    Article  CAS  PubMed  Google Scholar 

  43. Bach LA, Salemi R, Leeding KS. Roles of insulin-like growth factor (IGF) receptors and IGF-binding proteins in IGF-II-induced proliferation and differentiation of L6A1 rat myoblasts. Endocrinology 1995; 136: 5061–5069.

    Article  CAS  PubMed  Google Scholar 

  44. Coolican SA, Samuel DS, Ewton DZ, McWade FJ, Florini JR. The mitogenic and myogenic actions of insulin-like growth factors utilize distinct signaling pathways. J Biol Chem 1997; 272: 6653–6662.

    Article  CAS  PubMed  Google Scholar 

  45. Baserga R, Resnicoff M, D’Ambrosio C, Valentinis B: The role of the IGF-I receptor in apoptosis. Vitam Horm 1997; 53: 65–98.

    Article  CAS  PubMed  Google Scholar 

  46. Baserga R, Resnicoff M, Dews M. The IGF-I receptor and cancer. Endocrine 1997; 7: 99–102.

    Article  CAS  PubMed  Google Scholar 

  47. Hsu D, Olefsky JM. Effect of a major histocompatibility complex class I peptide on insulin-like growth factor I receptor internalization and biological signaling. Endocrinology 1993; 133: 1247–1251.

    Article  CAS  PubMed  Google Scholar 

  48. Resnicoff M, Huang Z, Herbert D, Abraham D, Baserga R. A novel class of peptides that induce apoptosis and abrogate tumorigenesis in vivo. Biochem Biophys Res Comm 1997; 240: 208–212.

    Article  CAS  PubMed  Google Scholar 

  49. Lafarge-Frayssinet C, Duc HT, Frayssinet C, Sarasin A, Anthony D, Guo Y, Trojan J. Antisense insulin-like growth factor I transferred into a rat hepatoma cell line inhibits tumorigenesis by modulating major histocompatibility complex 1 cell surface expression. Cancer Gene Ther 1997; 4: 276–285.

    CAS  PubMed  Google Scholar 

  50. Albert ML, Sauter B, Bhardway N. Dendritic cells acquire antigen from apoptotic cells and induce class 1-restricted CTLs. Nature 1998; 392: 86–89.

    Article  CAS  PubMed  Google Scholar 

  51. Marchand M, Weynants P, Rankin E, Arienti F, Belli F, Parmiani G, et al. Tumor regression responses in melanoma patients treated with a peptide encoded by gene MAGE-3. Int J Cancer 1998; 63: 883–885.

    Article  Google Scholar 

Download references

Authors
  1. Renato Baserga MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mariana Resnicoff PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Cancer Research Campaign, Molecular and Cellular Pharmacology Group, School of Biological Sciences, University of Manchester, UK

    John A. Hickman  & Caroline Dive  & 

Rights and permissions

Reprints and permissions

Copyright information

© 1999 Springer Science+Business Media New York

About this chapter

Cite this chapter

Baserga, R., Resnicoff, M. (1999). Insulin-Like Growth Factor-1 Receptor as a Target for Anticancer Therapy. In: Hickman, J.A., Dive, C. (eds) Apoptosis and Cancer Chemotherapy. Cancer Drug Discovery and Development. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-59259-720-8_13

Download citation

  • DOI: https://doi.org/10.1007/978-1-59259-720-8_13

  • Publisher Name: Humana Press, Totowa, NJ

  • Print ISBN: 978-1-61737-165-3

  • Online ISBN: 978-1-59259-720-8

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation